Caribou Q2 net loss $37.7M; extends cash runway to H2 2026 after 12% workforce cut

Caribou Biosciences, Inc.

2024-Q2 EPS reported -$0.88 revenue$5,893,000

Net loss $37.7M in Q2 2024 vs $29.5M in Q2 2023; cash & equivalents $311.8M at June 30, down from $372.4M.
Discontinued preclinical CAR-NK platform; reduced workforce ~12% to extend cash runway into H2 2026.
CB-010 ANTLER enrolling ~20 2L LBCL and ~10 prior CD19 relapsed patients; initial data expected H1 2025.
CB-011 CaMMouflage dose-escalation data for r/r multiple myeloma planned by year-end 2024.
Appointed autoimmune expert Terri Laufer, MD to SAB; CB-010 GALLOP lupus trial initiation expected by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.